IP Library › Granted Patent US 7,700,568
Granted Patent B2
US 7,700,568 · App. 09/750,410 · Granted Apr 20, 2010

Uses of DNA-PK

Assignee: Sloan-Kettering Institute for Cancer Research
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,700,568
App. No.
09/750,410
Granted
Apr 20, 2010
Kind
B2
Abstract

This invention provides methods for increasing the susceptibility of cells to DNA-damaging agents, and for treating tumors in a subject, comprising introducing antisense that prevent expression of DNA dependent protein kinase catalytic subunit Ku70 or Ku80, wherein the antisense is in an amount sufficient to increase the sensitivity of the cells and tumors to heat, chemical, or radiation-induced DNA damage.

Claims (3)

1. A method for increasing the susceptibility of a cell to a DNA-damaging agent, comprising introducing into the cell in vitro an antisense nucleic acid that specifically hybridizes to a nucleic acid encoding a human DNA-dependent protein kinase subunit so as to prevent expression of the human DNA-dependent protein kinase subunit wherein (a) the antisense nucleic acid is in an amount sufficient to increase the sensitivity of the cell to heat, chemical, or radiation-induced DNA damage, (b) the antisense oligonucleotide is enclosed in a liposome prior to introduction into the cell and (c) the antisense nucleic acid has the sequence of a human Ku70 cDNA in the antisense orientation or a human Ku80 cDNA in the antisense orientation, and wherein the sensitivity of the cell to 1 ug/ml adriamycin is increased by 3-5 fold or wherein the sensitivity of the cell to 6 Gy of γ-radiation is increased by approximately 5-fold.

2. The method of claim 1 , wherein the antisense nucleic acid has the sequence of human Ku70 cDNA in the antisense orientation and wherein the sensitivity of the cell to 6 Gy of γ-radiation is increased by approximately 5-fold.

3. The method of claim 1 , wherein the antisense nucleic acid has the sequence of human Ku80 cDNA in the antisense orientation, and wherein the sensitivity of the cell to 1 ug/ml adriamycin is increased by 3-5 fold.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 9, 2002
From: LI, GLORIA C.; BURGMAN, PAUL W. J. J.
To: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
Reel/Frame 013181/0530 →
Continuity (3)
Continuation PCTUS991470200 · Jun 30, 1999
Provisional Application 6009118100 · Jun 30, 1998
Related Publication 20030083276A1 · May 1, 2003